Lubiprostone: A novel treatment for chronic constipation

Clinical Interventions in Aging

Volumn 3, Issue 2, 2008, Pages 357-364

  Lacy, Brian E ^a   Levy, L Campbell ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Chloride; Chloride channels; Constipation; Functional bowel disorders; Gastrointestinal motility; Intestinal secretion; Irritable bowel syndrome; Lubiprostone

Indexed keywords

BISACODYL; CHLORIDE CHANNEL; CHLORIDE CHANNEL 2; FLEET; FLEET ENEMA; LUBIPROSTONE; OPIATE; PLACEBO;

ABDOMINAL CRAMP; ABDOMINAL PAIN; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; ELDERLY CARE; ELECTROCARDIOGRAPHY MONITORING; ELECTROLYTE BLOOD LEVEL; FETUS WASTAGE; HUMAN; IRRITABLE COLON; NAUSEA; NONHUMAN; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TERATOGENICITY; VOMITING; WEIGHT REDUCTION;

AGED; ALPROSTADIL; CHLORIDE CHANNELS; CONSTIPATION; GASTROINTESTINAL AGENTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 47849101126     PISSN: 11769092     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Brandt LJ, Prather CM, Quigley EMM, et al. 2005. Systematic review on the management of chronic constipation in North America. Am J Gastroenterol, 100:S5-S22.
2. Camilleri M, Bharucha AE, Ueno R, et al. 2006. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol, 290:G942-G7.
3. Cash BD, Lacy BE. 2006. Systematic review: FDA-approved prescription medications for adults with constipation. Gastroenterol Hepatol, 2:736-49.
4. Chen TY. 2005. Structure and function of ClC channels. Annu Rev Physiol, 67:809-39.
5. Crawford DF, Perentesis GP, Engelke KJ, et al. 2005. Effects of lubiprostone, a novel GI chloride channel activator, on reproductive and developmental toxicity endpoints in rats. Am J Gastroenterol, 100:S331.
6. Cuppoletti J, Malinowska DH, Tewari KP, et al. 2004. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol, 287:C1173-C83.
7. Dennison C, Prasad M, Lloyd A, et al. 2005. The health-related quality of life and economic burden of constipation. Pharmacoeconomics, 23:461-7.
8. DiPalma JA, Cleveland MV, McGowan J, et al. 2007. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J Gastroenterol, 102:1436-41.
9. Drossman DA, Chey WD, Panas R, et al. 2007. Lubiprostone significantly improves symptom relief rates in adults with irritable bowel syndrome and constipation (IBS-C): data from two, twelve-week, randomized, placebo-controlled, double blind trials. Gastroenterol, 132:2586-7.
10. Grider JR, Jin JG. 1994. Distinct populations of sensory neurons mediate the peristaltic reflex elicited by muscle stretch and mucosal stimulation. J Neurosci, 14: 2854-60.
11. Higgins PDR, Johanson JF. 2004. Epidemiology of chronic constipation in North America: A systematic review. Am J Gastroenterol, 99:750-9.
12. Irvine EJ, Ferrazzi S, Pare P, et al. 2002. Health-related quality of life in functional GI disorders: focus on constipation and resource utilization. Am J Gastroenterol, 97:1986-93.
13. Johanson JF, Gargano MA, Holland PC, et al. 2004. Phase III, randomized withdrawal study of RU-0211, a novel chloride channel activator for the treatment of constipation. Gastroenterol, 126:A298. Abstract 749.
14. Johanson JF, Gargano MA, Holland PC, et al. 2005a. Initial and sustained effects of lubiprostone, a chloride channel-2 (ClC-2) activator for the treatment of constipation: data from a 4-week Phase III study. Am J Gastroenterol, 100:A884.
15. Johanson JF, Gargano MA, Holland PC, et al. 2005b. Phase III study of lubiprostone, a chloride channel-2 (ClC-2) activator for the treatment of constipation: safety and primacy efficacy. Am J Gastroenterol, 100:A896.
16. Johanson JF, Morton D, Geenan J, et al. 2008. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol, 103:170-7.
17. Johanson JF, Panas R, Holland PC, et al. 2006a. Long-term efficacy of lubiprostone for the treatment of chronic constipation. Gastroenterol, 130:A317.
18. Johanson JF, Panas R, Holland PC, et al. 2006b. A dose-ranging, double-blind, placebo-controlled study of lubiprostone in subjects with irritable bowel syndrome and constipation (IBS-C). Gastroenterol, 130:A25.
19. Johanson JF, Ueno R. 2007. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther, 25:1351-61.
20. Lacy BE, Cole MS. 2004. Constipation in the older adult. Clinical Geriatr, 12:44-54.
21. Lipecka J, Bali M, Thomas A, et al. 2002. Distribution of ClC-2 chloride channel in rat and human epithelial tissues. Am J Physiol Cell Physiol, 282:C805-C16.
22. Longstreth GF, Thompson WG, Chey WD, et al. 2006. Functional bowel disorders. Gastroenterology, 130:1480-91.
23. Mindell JA, Maduke M. 2001. ClC chloride channels. Genome Bio, 2:3003.1-3003.6.
24. Muller-Lissner SA, Kamm MA, Scarpignato C, et al. 2005. Myths and misconceptions about chronic constipation. Am J Gastroenterol, 100:232-42.
25. Perentesis GP, Crawford DF, Engelke KJ, et al. 2005. Effects of lubiprostone, a novel GI chloride channel activator, on isolated smooth muscle. Am J Gastroenterol, 100:A900.
26. Rivera E, Wahle A, Joswick TR, et al. 2007. Lubiprostone, a novel type-2 chloride channel (Clc-2) activator, does not affect serum electrolyte balance in elderly and non-elderly patients with chronic idiopathic constipation. Gastroenterol, 132:A191-2.
27. Sprenger C, Copa A, Morganroth J, et al. 2007. Effect of lubiprostone, a unique agent for the treatment of chronic idiopathic constipation, on clinical electrocardiogram results. Gastroenterol, 132:A325.
28. Suzuki M, Morita T, Iwamoto T. 2006. Diversity of Cl channels. Cell Mol Life Sci, 63:12-24.
29. Talley NJ, Weaver AL, Zinsmeister AR, et al. 1992. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. Am J Epidemiol, 136:165-77.
30. Ueno R. 2005. Multiple, escalating, oral-dose study to assess the safety, tolerance, and pharmacodynamic profile of lubiprostone in normal healthy volunteers. Neurogastroenterol Motil, 17:626.
31. Ueno R, Hiroyoshi O, Engelke KJ. 2006d. Effect of lubiprostone on morphine-induced constipation and analgesia. Gastroenterol, 130:A373-4.
32. Ueno R, Joswick TR, Wahle A, et al. 2006a. Efficacy and safety of lubiprostone for the treatment of chronic constipation in male vs. female subjects. Gastroenterol, 130:A322.
33. Ueno R, Joswick TR, Wahle A, et al. 2006b. Efficacy and safety of lubiprostone for the treatment of chronic constipation in elderly vs. non-elderly subjects. Gastroenterol, 130:A189.
34. Ueno R, Osama H, Habe T, et al. 2004. Oral SPI-0211 increases intestinal fluid secretion and chloride concentration without altering serum electrolyte levels. Gastroenterol, 126:A298.
35. Ueno R, Panas R, Wahle A, et al. 2006c. Long-term efficacy and safety of lubiprostone for the treatment of chronic constipation in elderly subjects. Gastroenterol, 130:A188.
36. Young RJ, Beerman LE, Vanderhoof JA. 1998. Increasing oral fluids in chronic constipation in children. Gastroenterol Nurs, 21:156-61.
37. Zelnorm (tegaserod maleate) Information. 2007. FDA/Center for Drug Evaluation and Research. Accessed September 27, 2007. URL: www.fda.gov/ CDER/Drug/infopage/zelnorm/default.htm.